HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.

AuthorsTamar Tadmor, Ohad Benjamini, Andrei Braester, Galia Rahav, Lior Rokach
JournalLeukemia (Leukemia) Vol. 35 Issue 9 Pg. 2727-2730 (09 2021) ISSN: 1476-5551 [Electronic] England
PMID34376803 (Publication Type: Letter)
Chemical References
  • Antibodies, Viral
  • COVID-19 Vaccines
  • BNT162 Vaccine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Viral (blood, immunology)
  • Antibody Formation
  • BNT162 Vaccine
  • COVID-19 (complications, virology)
  • COVID-19 Vaccines (therapeutic use)
  • Case-Control Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell (blood, drug therapy, immunology, virology)
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • SARS-CoV-2 (isolation & purification)
  • COVID-19 Drug Treatment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: